ArticleNPJ vaccines2024
Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform.
Marcal Yll-Pico et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this paperpooled itcites it